Radioactive Bone Cement

Brief Description

The core innovation is a dosimetry-driven approach that determines the activity concentration of a radioisotope based on the distance between the cement surface and the target tissue, enabling predictable, volume‑independent radiation dosing.

Suggested uses

• Targeted Treatment of Bone Tumors
• Augmenting Vertebroplasty / Kyphoplasty with Therapeutic Radiation
• Radiation Delivery in Anatomically Constrained Areas
• Post‑Curettage Adjuvant Therapy
• Palliative Treatment for Painful Bone Metastases
• Multi‑Isotope Therapy for Optimized Dose Profiles
• Software‑Driven Personalized Dosimetry
• Radiation‑Sparing Applications
• Gamma‑Attenuated Cement for Deep or Irregular Targets
• Standardized, Volume‑Independent Brachytherapy

Advantages

• Predictable, Geometry‑Driven Radiation Dosing: Eliminates one of the biggest uncertainties in cement‑based brachytherapy. 
• Superior Protection of Healthy Tissue: Built‑in safety mechanism that minimizes radiation to spinal cord, nerves, and other critical structures. 
• Seamless Integration Into Existing Orthopedic Procedures: No new surgical tools or complex training required; easy adoption in vertebroplasty, kyphoplasty, and tumor curettage.
• Personalized, Software‑Driven Treatment Planning: Enables standardized, clinician‑friendly planning tools that support personalized therapy and reduce operator variability.
• Flexible Isotope Selection and Dose Shaping: Tailors penetration depth, dose rate, and duration to tumor biology and anatomical constraints. 
• Volume‑Independent Dose Distribution: Reliable therapy even when cement distribution is irregular or unpredictable in cancellous bone.
• Built‑In Radiation‑Sparing Algorithms: Reduces toxicity and expands eligibility for patients with tumors near sensitive structures.
• Enables Combined Structural + Radiotherapeutic Treatment: Single‑procedure treatment for painful or unstable metastatic lesions.
• Expands Brachytherapy to Previously Inaccessible Sites: Opens new therapeutic territory in spine oncology and orthopedic oncology.
• Supports Multi‑Phase Treatment Through Half‑Life Engineering: Optimizes tumor control without repeated interventions.

Full Description

This invention introduces a breakthrough approach to internal radiation therapy by transforming bone cement into a precision‑controlled brachytherapy source, where radiation dose is determined not by cement volume but by the measured distance between the cement surface and the target tissue. By mixing beta‑ or gamma‑emitting isotopes into a matrix engineered to attenuate emissions so that therapeutic radiation originates only from a thin layer near the surface, clinicians can deliver predictable, patient‑specific doses while sparing nearby healthy structures. The platform supports single or multi‑isotope formulations, integrates seamlessly with vertebral and orthopedic workflows, and enables software‑driven, distance‑based dosimetry that standardizes treatment and expands the therapeutic potential of cement‑based interventions.

Patent Status